Aquestive Therapeutics (AQST) Q1 2025 Earnings Call May 13, 2025 08:00 AM ET Speaker0 Good day, and thank you for standing by. Welcome to the Aquestive Therapeutics first quarter twenty twenty five earnings conference call. At this time, all participants are in a listen only mode. After the speakers' presentation, there'll be a question and answer session. Please be advised today's conference is being recorded. I would now like to turn the conference over to your host today, Brian Korb. Please go ahead. Spe ...

For the quarter ended March 2025, Aquestive Therapeutics (AQST) reported revenue of $8.72 million, down 27.6% over the same period last year. EPS came in at -$0.24, compared to -$0.17 in the year-ago quarter.The reported revenue represents a surprise of -28.14% over the Zacks Consensus Estimate of $12.14 million. With the consensus EPS estimate being -$0.17, the EPS surprise was -41.18%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations ...

Aquestive Therapeutics (AQST) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.17 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -41.18%. A quarter ago, it was expected that this specialty pharmaceutical company would post a loss of $0.14 per share when it actually produced a loss of $0.19, delivering a surprise of -35.71%.Over the last four ...

First Quarter 2025 Earnings Supplemental Materials September 2024 May 12, 2025 Advancing medicines. Solving problems. Improving lives. Advancing medicines. Solving problems. Improving lives. Advancing medicines. Solving problems. Improving lives. Advancing medicines. Solving problems. Improving lives. ® Disclaimer Certain statements in this press release include "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "believe," "anticipate," "pl ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number: 001-38599 Aquestive Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) (State or other jurisdiction of Inco ...

Exhibit 99.1 Anaphylm™ (epinephrine) Sublingual Film Aquestive has completed the submission of its New Drug Application (NDA) for Anaphylm with the U.S. Food and Drug Administration (FDA). The NDA includes data from the full adult clinical program and the recently completed pediatric study. Topline results from the pediatric trial in patients aged 7 to 17 demonstrated a pharmacokinetic (PK) profile consistent with prior adult clinical data, supporting a proposed label aligned with the 0.3 mg epinephrine aut ...

Submitted NDA for Anaphylm™ (epinephrine), the first and only oral sublingual film for patients with severe allergic reactions Advancing commercial readiness efforts with a planned Q1 2026 launch of Anaphylm, subject to FDA approvalCompany to host investor call on May 13, 2025, at 8:00am ET WARREN, N.J., May 12, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives t ...

Aquestive Therapeutics (AQST) 2025 Conference May 08, 2025 10:00 AM ET Speaker0 Thank you everybody. Good morning and welcome to the Citizens Life Science Conference. Really excited to be joined next by Aquestive Therapeutics. Aquestive is a company that has, successfully leveraged its oral film technology through multiple approved products. Our focus right now, the company's focus is, ANNAFILM, which is an oral film, epinephrine formulation for severe allergy. Company recently submitted the NDA, so so, you ...

WARREN, N.J., May 05, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, announced today that the management team will participate in the upcoming Citizens Life Sciences Conference from May 7-8 in New York City. The Aquestive team will hold a fireside chat on May 8th at 10 am ET; management will also be hosting ...

Group 1 - The investment style described is termed "Fundamental Options," which combines fundamental analysis with options trading strategies [1] - The strategies pursued include income-oriented investments, particularly in Business Development Companies (BDCs) and Utilities, as well as growth investments in technology at reasonable prices [1] - The investment approach also encompasses deep value strategies based on Discounted Cash Flow and other industry-specific valuation methods, along with a focus on Dividend Aristocrats [1] Group 2 - The investor typically engages in long-term stock investments while also employing 20-25 options strategies for various purposes, including hedging, bullish substitutes, neutral trades, trading volatility, and earnings-related trades [1] - There is a passion for teaching and coaching in various life areas, including the authorship of a free local investing newsletter [1]